In the event that J&J and/or Apollo are required to make payment(s) to ES Therapeutics pursuant to the underlying agreements, Avalo will recognize revenue under its existing contracts with those cust…
Avalo Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AVTX-DEBT-8002
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
AVTX-DEBT
Debt stack $427,000
90%
Market cache reports total debt of $427,000.
AVTX-DEBT-8001
Warrants outstanding: 4000000
90%
xbrl warrant detail from xbrl 2025-12-31.
Avalo Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Avalo Therapeutics, Inc..
Avalo Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
AVTX-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 101 tracked holders.
Avalo Therapeutics, Inc. Extended Supply Chain Network